GlassScriptPhysician profile
Lauren Lanier
NPI 1356856272
$12,516.96
in general payments reported to CMS, 2019-2025
39 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,769 · 2022: $2,425 · 2023: $3,178 · 2024: $3,399 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,322.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,652.30 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,862.77 | 2021-2025 | |
| Novo Nordisk INC | $1,193.21 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $895.63 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $826.00 | 2021-2025 | |
| Dexcom, INC. | $796.64 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amgen INC. | $688.86 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.47 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $449.26 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $382.24 | 2022 | |
| Boston Scientific Corporation | $247.84 | 2021-2024 | Watchman Flx |
| Abbott Laboratories | $226.56 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $177.23 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $170.34 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $133.44 | 2024-2025 | Voquezna |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.